ifosfamide has been researched along with Neoplasms, Pleural in 27 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| ", ifosfamide (5 g/m (2) on day 1), carboplatin (300 mg/m (2) on day 1) and etoposide (150 mg/m (2) on days 2 and 3), administered every 4 weeks, to assess the treatment benefit for patients with malignant pleural mesothelioma." | 9.11 | [Evaluation of the therapeutic benefit of 41.8 degrees C whole body hyperthermia plus ifosfamide, carboplatin and etoposide (ICE) for patients with malignant pleural mesothelioma using the Modified Brunner-Score (MBS)]. ( Bakhshandeh, A; Bruns, I; Kohlmann, T; Wiedemann, GJ, 2004) |
| " ifosfamide (5 g/m(2)), carboplatin (300 mg/m(2)) and etoposide (150 mg/m(2) on days 2 and 3), administered every 4 weeks, for patients with malignant pleural mesothelioma." | 9.10 | Ifosfamide, carboplatin and etoposide combined with 41.8 degrees C whole body hyperthermia for malignant pleural mesothelioma. ( Bakhshandeh, A; Bruns, I; Dalhoff, K; Demedts, A; Eberhardt, K; Ehlers, EM; Gatzemeier, U; Gruber, Y; Hegewisch-Becker, S; Kaukel, E; Kohlmann, T; Koschel, G; Peters, SO; Robins, HI; Traynor, A; Wiedemann, GJ; Zumschlinge, R, 2003) |
| "The current study was conducted to assess the activity and toxicity of high-dose ifosfamide and mesna with recombinant human granulocyte-colony-stimulating factor (rhG-CSF), given in an outpatient setting, in the treatment of patients with unresectable malignant mesothelioma." | 9.10 | High-dose ifosfamide with mesna and granulocyte-colony-stimulating factor (recombinant human G-CSF) in patients with unresectable malignant mesothelioma. ( Antman, KH; Baker, LH; Balcerzak, SP; Bhoopalam, N; Chapman, RA; Middleman, EL; Rankin, C; Talbot, SM; Taub, RN, 2003) |
| "This study investigated the feasibility and efficacy of doxorubicin dose-escalated chemotherapy in combination with ifosfamide in patients with malignant mesothelioma." | 9.07 | A phase II trial of dose-escalated doxorubicin and ifosfamide/mesna in patients with malignant mesothelioma. ( Corthouts, B; Dirix, LY; Prové, A; Schrijvers, D; van Marck, E; van Meerbeeck, J; van Oosterom, AT; Vermeire, P, 1994) |
| "Twenty-six patients with unresectable diffuse malignant mesothelioma were enrolled in Southwest Oncology Group (SWOG) study 8731 and treated with ifosfamide, 2 g/m2 intravenously for 4 days, and mesna 2 g/m2 intravenously for 5 days, every 3 weeks." | 9.07 | A phase II evaluation of ifosfamide and mesna in unresectable diffuse malignant mesothelioma. A Southwest Oncology Group study. ( Balcerzak, SP; Berenberg, JL; Keppen, MD; Metch, B; Militello, L; Pierce, HI; Zidar, BL, 1992) |
| "Forty three patients with histologically confirmed malignant mesothelioma were entered onto an Eastern Cooperative Oncology Group phase II study of ifosfamide given with mesna." | 9.07 | An extended phase II trial of ifosfamide plus mesna in malignant mesothelioma. ( Borden, EC; Falkson, CI; Falkson, G; Hayes, JA; Hunt, M; Smith, TJ, 1992) |
| "We report a case of retroperitoneal dedifferentiated liposarcoma treated effectively with high-dose ifosfamide." | 7.70 | [A case of advanced retroperitoneal dedifferentiated liposarcoma treated effectively with high-dose ifosfamide]. ( Fujinami, K; Kondoh, I; Kondoh, K; Kushida, K; Miura, T, 1999) |
| "Malignant mesothelioma is a rare malignancy with a median survival, ranging from 4 to 18 months in untreated patients." | 6.69 | Ifosfamide in malignant mesothelioma: a phase II study. ( Andersen, MK; Damgaard, K; Krarup-Hansen, A; Mårtensson, G; Olling, S; Thylen, A; Wallin, J; Winther-Nielsen, H, 1999) |
| ", ifosfamide (5 g/m (2) on day 1), carboplatin (300 mg/m (2) on day 1) and etoposide (150 mg/m (2) on days 2 and 3), administered every 4 weeks, to assess the treatment benefit for patients with malignant pleural mesothelioma." | 5.11 | [Evaluation of the therapeutic benefit of 41.8 degrees C whole body hyperthermia plus ifosfamide, carboplatin and etoposide (ICE) for patients with malignant pleural mesothelioma using the Modified Brunner-Score (MBS)]. ( Bakhshandeh, A; Bruns, I; Kohlmann, T; Wiedemann, GJ, 2004) |
| " ifosfamide (5 g/m(2)), carboplatin (300 mg/m(2)) and etoposide (150 mg/m(2) on days 2 and 3), administered every 4 weeks, for patients with malignant pleural mesothelioma." | 5.10 | Ifosfamide, carboplatin and etoposide combined with 41.8 degrees C whole body hyperthermia for malignant pleural mesothelioma. ( Bakhshandeh, A; Bruns, I; Dalhoff, K; Demedts, A; Eberhardt, K; Ehlers, EM; Gatzemeier, U; Gruber, Y; Hegewisch-Becker, S; Kaukel, E; Kohlmann, T; Koschel, G; Peters, SO; Robins, HI; Traynor, A; Wiedemann, GJ; Zumschlinge, R, 2003) |
| "The current study was conducted to assess the activity and toxicity of high-dose ifosfamide and mesna with recombinant human granulocyte-colony-stimulating factor (rhG-CSF), given in an outpatient setting, in the treatment of patients with unresectable malignant mesothelioma." | 5.10 | High-dose ifosfamide with mesna and granulocyte-colony-stimulating factor (recombinant human G-CSF) in patients with unresectable malignant mesothelioma. ( Antman, KH; Baker, LH; Balcerzak, SP; Bhoopalam, N; Chapman, RA; Middleman, EL; Rankin, C; Talbot, SM; Taub, RN, 2003) |
| "This study investigated the feasibility and efficacy of doxorubicin dose-escalated chemotherapy in combination with ifosfamide in patients with malignant mesothelioma." | 5.07 | A phase II trial of dose-escalated doxorubicin and ifosfamide/mesna in patients with malignant mesothelioma. ( Corthouts, B; Dirix, LY; Prové, A; Schrijvers, D; van Marck, E; van Meerbeeck, J; van Oosterom, AT; Vermeire, P, 1994) |
| "Twenty-six patients with unresectable diffuse malignant mesothelioma were enrolled in Southwest Oncology Group (SWOG) study 8731 and treated with ifosfamide, 2 g/m2 intravenously for 4 days, and mesna 2 g/m2 intravenously for 5 days, every 3 weeks." | 5.07 | A phase II evaluation of ifosfamide and mesna in unresectable diffuse malignant mesothelioma. A Southwest Oncology Group study. ( Balcerzak, SP; Berenberg, JL; Keppen, MD; Metch, B; Militello, L; Pierce, HI; Zidar, BL, 1992) |
| "Forty three patients with histologically confirmed malignant mesothelioma were entered onto an Eastern Cooperative Oncology Group phase II study of ifosfamide given with mesna." | 5.07 | An extended phase II trial of ifosfamide plus mesna in malignant mesothelioma. ( Borden, EC; Falkson, CI; Falkson, G; Hayes, JA; Hunt, M; Smith, TJ, 1992) |
| " The patient received ifosfamide (5 g/m2, day 1), carboplatin (300 mg/m2, day 1), etoposide (150 mg/m2, days 2-3) combined with WBH at 41." | 3.79 | [Chemotherapy in combination with whole-body hyperthermia in advanced malignant pleural mesothelioma]. ( Bakhshandeh, A; Bruns, I; Eberhardt, K; Wiedemann, GJ, 2000) |
| "We report a case of retroperitoneal dedifferentiated liposarcoma treated effectively with high-dose ifosfamide." | 3.70 | [A case of advanced retroperitoneal dedifferentiated liposarcoma treated effectively with high-dose ifosfamide]. ( Fujinami, K; Kondoh, I; Kondoh, K; Kushida, K; Miura, T, 1999) |
| "Malignant mesothelioma is a rare malignancy with a median survival, ranging from 4 to 18 months in untreated patients." | 2.69 | Ifosfamide in malignant mesothelioma: a phase II study. ( Andersen, MK; Damgaard, K; Krarup-Hansen, A; Mårtensson, G; Olling, S; Thylen, A; Wallin, J; Winther-Nielsen, H, 1999) |
| "Proximal epithelioid sarcoma (PES) originating from the pleura is a clinical entity rarely reported in the literature." | 2.53 | [Pleural epithelioid sarcoma: about a case and review of the literature]. ( Akasbi, Y; Amara, B; Arifi, S; Chatar, A; Fatemi, H; Lemrabet, FZ; Mellas, N; Ouahbi, H; Oualla, K; Tizniti, S, 2016) |
| "Rhabdomyosarcoma is an aggressive malignant tumor of childhood, originating from immature cells that are destinated to form striated skeletal muscle." | 1.43 | Primary diffuse pleural rhabdomyosarcoma in an adult patient. ( Bugdayci, M; Emri, S; Gedikoglu, G; Ibrahimov, F; Koksal, D, 2016) |
| "Primary pleural synovial sarcoma is a rare disease with poor outcomes." | 1.36 | Radiological assessment following thermoradiation therapy for primary pleural synovial sarcoma: case report. ( Abe, K; Furuhashi, S; Maebayashi, T; Sakaguchi, M; Shizukuishi, T; Sugitani, M; Takahashi, M; Tanaka, Y; Uematsu, A, 2010) |
| "Due to ifosfamide urotoxicity, encephalopathy is a frequent complication accompanying treatment with this drug." | 1.30 | [Ifosfamide-related encephalopathy. Report of two cases]. ( Coutant, G; Daly, JP; Desrame, J; Dourthe, LM; Merrer, J, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (7.41) | 18.7374 |
| 1990's | 7 (25.93) | 18.2507 |
| 2000's | 10 (37.04) | 29.6817 |
| 2010's | 8 (29.63) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pannu, AK | 1 |
| Sharma, N | 1 |
| Al-Hader, AA | 1 |
| Jain, A | 1 |
| Al-Nasrallah, N | 1 |
| Einhorn, LH | 1 |
| Koksal, D | 1 |
| Ibrahimov, F | 1 |
| Bugdayci, M | 1 |
| Gedikoglu, G | 1 |
| Emri, S | 1 |
| Nakamura, Y | 1 |
| Teramoto, Y | 1 |
| Sato, S | 1 |
| Fujisawa, Y | 1 |
| Yamada, K | 1 |
| Yamamoto, A | 1 |
| Sugitani, A | 1 |
| Asai, K | 1 |
| Kojima, K | 1 |
| Eguchi, Y | 1 |
| Kawaguchi, T | 1 |
| Ohsawa, M | 1 |
| Hirata, K | 1 |
| Ouahbi, H | 1 |
| Akasbi, Y | 1 |
| Oualla, K | 1 |
| Amara, B | 1 |
| Chatar, A | 1 |
| Tizniti, S | 1 |
| Fatemi, H | 1 |
| Lemrabet, FZ | 1 |
| Arifi, S | 1 |
| Mellas, N | 1 |
| Stacchiotti, S | 1 |
| Saponara, M | 1 |
| Frapolli, R | 1 |
| Tortoreto, M | 1 |
| Cominetti, D | 1 |
| Provenzano, S | 1 |
| Negri, T | 1 |
| Dagrada, GP | 1 |
| Gronchi, A | 1 |
| Colombo, C | 1 |
| Vincenzi, B | 1 |
| Badalamenti, G | 1 |
| Zuco, V | 1 |
| Renne, SL | 1 |
| Collini, P | 1 |
| Morosi, C | 1 |
| Dei Tos, AP | 1 |
| Bello, E | 1 |
| Pilotti, S | 1 |
| Casali, PG | 1 |
| D'Incalci, M | 1 |
| Zaffaroni, N | 1 |
| Lin, HH | 1 |
| Lin, JN | 1 |
| Berry, MF | 1 |
| Sporn, TA | 1 |
| Moore, JO | 1 |
| D'Amico, TA | 1 |
| Abe, K | 1 |
| Maebayashi, T | 1 |
| Shizukuishi, T | 1 |
| Sakaguchi, M | 1 |
| Furuhashi, S | 1 |
| Takahashi, M | 1 |
| Tanaka, Y | 1 |
| Uematsu, A | 1 |
| Sugitani, M | 1 |
| Bakhshandeh, A | 3 |
| Bruns, I | 3 |
| Traynor, A | 1 |
| Robins, HI | 1 |
| Eberhardt, K | 2 |
| Demedts, A | 1 |
| Kaukel, E | 1 |
| Koschel, G | 1 |
| Gatzemeier, U | 1 |
| Kohlmann, T | 2 |
| Dalhoff, K | 1 |
| Ehlers, EM | 1 |
| Gruber, Y | 1 |
| Zumschlinge, R | 1 |
| Hegewisch-Becker, S | 1 |
| Peters, SO | 1 |
| Wiedemann, GJ | 3 |
| Talbot, SM | 1 |
| Rankin, C | 1 |
| Taub, RN | 1 |
| Balcerzak, SP | 2 |
| Bhoopalam, N | 1 |
| Chapman, RA | 1 |
| Baker, LH | 1 |
| Middleman, EL | 1 |
| Antman, KH | 1 |
| Eichelberger, L | 1 |
| Jones, TD | 1 |
| Vance, G | 1 |
| Saxena, R | 1 |
| Indolfi, P | 1 |
| Bisogno, G | 1 |
| Casale, F | 1 |
| Cecchetto, G | 1 |
| De Salvo, G | 1 |
| Ferrari, A | 1 |
| Donfrancesco, A | 1 |
| Donofrio, V | 1 |
| Martone, A | 1 |
| Di Martino, M | 1 |
| Di Tullio, MT | 1 |
| Dirix, LY | 1 |
| van Meerbeeck, J | 1 |
| Schrijvers, D | 1 |
| Corthouts, B | 1 |
| Prové, A | 1 |
| van Marck, E | 1 |
| Vermeire, P | 1 |
| van Oosterom, AT | 1 |
| Dourthe, LM | 1 |
| Coutant, G | 1 |
| Desrame, J | 1 |
| Merrer, J | 1 |
| Daly, JP | 1 |
| Andersen, MK | 1 |
| Krarup-Hansen, A | 1 |
| Mårtensson, G | 1 |
| Winther-Nielsen, H | 1 |
| Thylen, A | 1 |
| Damgaard, K | 1 |
| Olling, S | 1 |
| Wallin, J | 1 |
| Fujinami, K | 1 |
| Kondoh, K | 1 |
| Kondoh, I | 1 |
| Miura, T | 1 |
| Kushida, K | 1 |
| Veronesi, G | 1 |
| Spaggiari, L | 1 |
| Mazzarol, G | 1 |
| De Pas, M | 1 |
| Leo, F | 1 |
| Solli, P | 1 |
| Pastorino, U | 1 |
| Granata, C | 1 |
| Gambini, C | 1 |
| Carlini, C | 1 |
| Repetto, P | 1 |
| Torre, M | 1 |
| Mazzola, C | 1 |
| Mattioli, G | 1 |
| Jasonni, V | 1 |
| Smith, IE | 1 |
| Zidar, BL | 1 |
| Metch, B | 1 |
| Pierce, HI | 1 |
| Militello, L | 1 |
| Keppen, MD | 1 |
| Berenberg, JL | 1 |
| Falkson, G | 2 |
| Hunt, M | 1 |
| Borden, EC | 1 |
| Hayes, JA | 1 |
| Falkson, CI | 1 |
| Smith, TJ | 1 |
| Carmichael, J | 1 |
| Cantwell, BM | 1 |
| Harris, AL | 1 |
| Alberts, AS | 1 |
| Van Zyl, L | 1 |
2 reviews available for ifosfamide and Neoplasms, Pleural
| Article | Year |
|---|---|
[Pleural epithelioid sarcoma: about a case and review of the literature].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Fatal Outcome; Female; Humans; I | 2016 |
[Chemotherapy in combination with whole-body hyperthermia in advanced malignant pleural mesothelioma].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 2000 |
9 trials available for ifosfamide and Neoplasms, Pleural
| Article | Year |
|---|---|
Ifosfamide, carboplatin and etoposide combined with 41.8 degrees C whole body hyperthermia for malignant pleural mesothelioma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Dexame | 2003 |
High-dose ifosfamide with mesna and granulocyte-colony-stimulating factor (recombinant human G-CSF) in patients with unresectable malignant mesothelioma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Disease-Free Survival; Drug Thera | 2003 |
[Evaluation of the therapeutic benefit of 41.8 degrees C whole body hyperthermia plus ifosfamide, carboplatin and etoposide (ICE) for patients with malignant pleural mesothelioma using the Modified Brunner-Score (MBS)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Humans; Hyperthermia, Induce | 2004 |
A phase II trial of dose-escalated doxorubicin and ifosfamide/mesna in patients with malignant mesothelioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Feasibility Studies; Femal | 1994 |
Ifosfamide in malignant mesothelioma: a phase II study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Humans; Ifosfamide; Male; Mesothelioma; Middle Aged; | 1999 |
[Chemotherapy in combination with whole-body hyperthermia in advanced malignant pleural mesothelioma].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 2000 |
Carboplatin in small cell lung cancer: the Royal Marsden Hospital experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell | 1992 |
A phase II evaluation of ifosfamide and mesna in unresectable diffuse malignant mesothelioma. A Southwest Oncology Group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Ifosfamide; Male; Mesna | 1992 |
An extended phase II trial of ifosfamide plus mesna in malignant mesothelioma.
Topics: Drug Administration Schedule; Female; Humans; Ifosfamide; Infusions, Intravenous; Kidney Diseases; M | 1992 |
17 other studies available for ifosfamide and Neoplasms, Pleural
| Article | Year |
|---|---|
Neurofibromatosis type 1 and disseminated malignant peripheral nerve sheath tumor.
Topics: Antineoplastic Agents; Cafe-au-Lait Spots; Disease Management; Doxorubicin; Humans; Ifosfamide; Lung | 2017 |
Metastatic malignant transformation of teratoma to primitive neuroectodermal tumor (PNET): results with PNET-based chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyclophosphamide; Doxorubicin | 2015 |
Primary diffuse pleural rhabdomyosarcoma in an adult patient.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Fatal Outcome; Humans; Ifosf | 2016 |
Long-term control of pleural metastasis in Stewart-Treves syndrome with single-agent chemotherapies followed by maintenance chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Doxorubicin; Drug Administration Schedule | 2015 |
Primary Pleural Synovial Sarcoma Treated with Pazopanib.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chest Pain; Doxorubicin; Dyspnea; Fatal Outco | 2015 |
Patient-derived solitary fibrous tumour xenografts predict high sensitivity to doxorubicin/dacarbazine combination confirmed in the clinic and highlight the potential effectiveness of trabectedin or eribulin against this tumour.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cerebellar | 2017 |
Tender nodules on the palms and soles after chemotherapy.
Topics: Aged; Antibiotics, Antineoplastic; Carcinoma; Drug-Related Side Effects and Adverse Reactions; Epiru | 2008 |
Giant thoracic liposarcoma treated with induction chemotherapy followed by surgical resection.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Doxorubicin; Human | 2009 |
Radiological assessment following thermoradiation therapy for primary pleural synovial sarcoma: case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Combined Modality Therapy; Cyclop | 2010 |
A 37-year-old man with a pleural mass.
Topics: Adult; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Chemotherapy, Adjuvant; Chromosomes, Hu | 2005 |
Prognostic factors in pleuro-pulmonary blastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Child; Child, P | 2007 |
[Ifosfamide-related encephalopathy. Report of two cases].
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Dise | 1999 |
[A case of advanced retroperitoneal dedifferentiated liposarcoma treated effectively with high-dose ifosfamide].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Combined Modality | 1999 |
Huge malignant localized fibrous tumor of the pleura.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Doxorubicin; Fibroma; Hum | 2000 |
Pleuropulmonary blastoma.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Child, Preschool; Dactinomycin; Disease-Free Survival | 2001 |
A phase II trial of ifosfamide/mesna with doxorubicin for malignant mesothelioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Evaluation; Female; H | 1989 |
Malignant pleural mesothelioma: phase II pilot study of ifosfamide and mesna.
Topics: Adolescent; Adult; Aged; Drug Evaluation; Female; Humans; Ifosfamide; Kidney Diseases; Male; Mercapt | 1988 |